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Treatment with a 2-week course of anti-CD154 antibody and a single transfusion of donor leukocytes (a
donor-specific transfusion or DST) permits skin allografts to survive for >100 days in thymectomized mice. As
clinical trials of this methodology in humans are contemplated, concern has been expressed that viral infection
of graft recipients may disrupt tolerance to the allograft. We report that acute infection with lymphocytic
choriomeningitis virus (LCMV) induced allograft rejection in mice treated with DST and anti-CD154 antibody
if inoculated shortly after transplantation. Isografts resisted LCMV-induced rejection, and the interferon-
inducing agent polyinosinic:polycytidylic acid did not induce allograft rejection, suggesting that the effect of
LCMV is not simply a consequence of nonspecific inflammation. Administration of anti-CD8 antibody to
engrafted mice delayed LCMV-induced allograft rejection. Pichinde virus also induced acute allograft rejec-
tion, but murine cytomegalovirus and vaccinia virus (VV) did not. Injection of LCMV ;50 days after tolerance
induction and transplantation had minimal effect on subsequent allograft survival. Treatment with DST and
anti-CD154 antibody did not interfere with clearance of LCMV, but a normally nonlethal high dose of VV
during tolerance induction and transplantation killed graft recipients. We conclude that DST and anti-CD154
antibody induce a tolerant state that can be broken shortly after transplantation by certain viral infections.
Clinical application of transplantation tolerance protocols may require patient isolation to facilitate the
procedure and to protect recipients.
Among the most important risks faced by allograft recipients
are viral infections. These may arise from infected transplanted
organs, from the reactivation of latent host viruses as a conse-
quence of an allogeneic stimulus and immunosuppressive
treatment, or from exposure of the immunosuppressed host to
exogenous environmental pathogens (3, 5, 12, 17, 23).
Recent developments in our understanding of T-cell activa-
tion, anergy, and tolerance have led to treatment protocols that
permit durable graft survival without the need for prolonged
immunosuppressive therapy. These protocols are based on in-
terference with costimulatory signal pathways. When naı¨ve T
cells encounter antigen, they require ligation of both the T-cell
receptor (“signal 1”) and certain costimulatory molecules
(“signal 2”) in order to proliferate and differentiate. Signal 1 in
the absence of signal 2 leads to anergy or possibly apoptosis
(21). One important costimulatory molecule is CD154 (CD40
ligand), which binds to CD40 on antigen-presenting cells (6,
11, 14).
We have shown in mice that a very brief course of anti-
CD154 antibody together with a single transfusion of alloge-
neic splenocytes prolongs the survival of fully allogeneic skin
grafts (16). About 20% of grafts survive for .275 days in
euthymic recipients (16), and the majority survive for .100
days in thymectomized recipients (15). Although we initially
interpreted graft survival to be the result of anergy of effector
T-cell populations (16), the mechanism appears to be more
complex. For example, tolerance to the allograft can be abro-
gated by treatment of recipients with antibody to CD4 (15).
The data suggest that allograft rejection, which is normally
mediated by CD81 T cells, may be regulated by a CD41 T-cell
population that arises as a consequence of the tolerization
procedure. Whatever the mechanism, donor-specific transfu-
sion (DST) and anti-CD154 antibody treatment are being stud-
ied intensively for possible use in human transplantation (20).
This two-element tolerance induction protocol is simple and
appears benign, but its adaptation in the clinic will require
documentation of the safety and durability of transplanted
allografts. The requirement for CD41 T cells to maintain al-
lotolerance in this system suggests that allograft survival could
be unstable in the presence of infection, which may signifi-
cantly disrupt immune regulation and CD41-to-CD81 T-cell
ratios. Many viral infections not only induce transient shifts in
the CD4/CD8 ratio from 2:1 to 1:2 or 1:3 but also induce
cytotoxic T lymphocytes (CTLs) lytic to uninfected allogeneic
targets (4, 19, 25, 26, 28). The degeneracy of the T-cell re-
sponse to viral infection is such that many virus-specific T-cell
clones cross-react with specific allogeneic major histocompat-
ibility complex (MHC) antigens expressed on cells not infected
with the virus (1, 2, 19, 22). Such cross-reactivity between viral
antigens and alloantigens has been observed in T cells isolated
from mice infected with lymphocytic choriomeningitis virus
(LCMV), vaccinia virus (VV), Pichinde virus (PV), and murine
cytomegalovirus (MCMV) (19). It has also been observed in T
cells from humans infected with Epstein-Barr virus (4, 25, 26,
28). Recent studies have documented at the molecular level
how the T-cell receptor (TcR) of virus-specific T cells may
interact with allogeneic MHC molecules expressing endoge-
nous peptides (1, 4, 7, 24). Virus infections also have the
potential to overcome T-cell unresponsiveness by inducing
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high levels of interleukin-2 and other cytokines (9, 10, 10). The
present studies were designed to determine whether viral in-
fection of C57BL/6 (H2b) mice treated with BALB/c (H2d)
DST and anti-CD154 monoclonal antibody (MAb) and trans-
planted with allogeneic BALB/c skin grafts would influence
graft survival.
MATERIALS AND METHODS
Animals. C57BL/6 (H2b) and MHC-incompatible BALB/c (H2d) mice were
obtained from the National Cancer Institute (Frederick, Md.). In all experi-
ments, male C57BL/6 recipients and female BALB/c skin and DST donors were
used. All animals were certified to be free of Sendai virus, pneumonia virus of
mice, murine hepatitis virus, minute virus of mice, ectromelia virus, lactate
dehydrogenase-elevating virus, mouse poliovirus, reovirus type 3 virus, murine
adenovirus, LCMV, polyomavirus, Mycoplasma pulmonis, and Encephalitozoon
cuniculi. All animals were housed in microisolator cages and given ad libitum
access to autoclaved food. They were maintained in accordance with recommen-
dations in the Guide for the care and use of laboratory animals (11a) and the
guidelines of the Institutional Animal Care and Use Committee (IACUC) of the
University of Massachusetts Medical School.
Transplantation procedures. Thymectomized male C57BL/6 recipients 6
weeks of age were tolerized and transplanted, using previously published tech-
niques (15, 16). Briefly, 107 BALB/c splenocytes from adult female donors were
injected intravenously in a volume of 0.5 ml into recipients 7 days before grafting.
Four doses of anti-CD154 MAb (0.25 mg) were administered intraperitoneally
(i.p.) twice weekly beginning on the day of spleen cell injection. BALB/c skin
grafts 1 to 2 cm in diameter were transplanted onto the dorsal flanks of C57BL/6
mice 7 days after the spleen cell injection and the initiation of anti-CD154 MAb
treatment. Graft rejection was defined as the first day on which the entire graft
was rejected (15, 16). In one experiment, thymectomized graft recipients treated
with DST and anti-CD154 MAb were given the interferon-inducing agent poly-
inosinic:polycytidylic acid (poly I:C; Sigma, St. Louis, Mo.) at a dose (each) of 0.5
mg intravenously 1 day after graft placement.
Transplantation recipients were thymectomized for two reasons. First, after
tolerization they maintain skin allografts for prolonged periods, often indefi-
nitely, thereby permitting long-term studies (15). Second, thymectomy permitted
us to define the effects of viral infection on tolerized lymphocyte populations in
the absence of new thymic emigrants in the periphery.
Virus infection procedures. In most experiments, mice were inoculated i.p.
with 5 3 104 PFU of LCMV strain Armstrong propagated in baby hamster
kidney cells. In the C57BL/6 (H2b) mouse, the LCMV Armstrong strain induces
a particularly high virus-specific CTL response and, in addition, significant levels
of cytotoxicity against uninfected target cells expressing H2d MHC alloantigens
(19, 28). In other experiments, mice were inoculated with varying concentrations
of VV, strain WR, MCMV strain Smith, PV, or PV strain AN3739 (28). Routes
of administration are indicated in the descriptions of the individual experiments.
LCMV, VV, MCMV, and PV have all been reported to induce anti-H2d allospe-
cific CTLs in C57BL/6 mice (28). Certain mice were inoculated with recombinant
VV expressing the gene for the LCMV glycoprotein (VV-GP) or the gene for the
LCMV nucleoprotein (VV-NP); both viruses were the kind gift of J. Lindsay
Whitton, Scripps Research Institute, La Jolla, Calif. (27, 28).
CTL assay. CTL analysis for virus-specific killing was performed by chromium-
51-release microcytotoxicity assays on LCMV-infected syngeneic MC57G (H2b)
target cells and control uninfected syngeneic target cells as previously described
(19). Allospecific CTL activity induced by virus infection was analyzed on unin-
fected P-815 (H2d) target cells.
Statistics. Average duration of graft survival is presented as the median. Graft
survival among groups was compared by the method of Kaplan and Meier (13).
The equality of allograft survival distributions for animals in different treatment
groups was tested by using the log rank statistic (13). P values of ,0.05 were
considered statistically significant.
RESULTS
Infection with LCMV abrogates transplantation tolerance
to skin allografts. Skin allograft recipients treated with DST
and anti-CD154 MAb and then infected with LCMV 1 day
after transplantation uniformly rejected their grafts (Fig. 1A).
In the majority of cases, the earliest signs of rejection appeared
10 to 11 days after infection, but in some cases, signs of rejec-
tion did not appear for nearly a month. In contrast, more than
half of skin allografts in uninfected mice treated with DST and
anti-CD154 MAb survived permanently. Median graft survival
time (MST) was .308 days in controls versus 26 days in
LCMV-infected recipients (P , 0.001).
In contrast, LCMV infection at progressively later time
points after tolerance induction had progressively less effect on
graft survival. Skin allograft recipients treated with DST and
anti-CD154 MAb and then infected with LCMV 15 days after
transplantation experienced a rate of survival that was only
somewhat compromised (Fig. 1B). MST after infection was 78
days in LCMV-infected recipients versus .293 days in controls
(P 5 0.06).
Survival of skin allografts in recipients treated with DST and
anti-CD154 MAb and then infected with LCMV 29 days after
transplantation was not statistically different from that ob-
served in controls (Fig. 1C). MST of grafts after infection was
104 days in LCMV-infected recipients versus .279 days in
controls (P 5 0.54).
Survival of skin allografts in tolerized recipients infected
with LCMV 51 to 57 days after transplantation was indistin-
guishable from that in controls (Fig. 1D). In this arm of the
experiment, eight mice received LCMV 51 to 57 days after
transplantation. Three of the eight mice received no other
intervention. One mouse rejected its graft 60 days after LCMV
inoculation; the remaining two survived through the end of the
experiment. As an additional test of the durability of tolerance,
the other five tolerized recipients that had been infected with
LCMV on days 51 to 57 after grafting were challenged with a
second virus on day 47 after LCMV infection. They were in-
oculated with 106 PFU of VV directly into their grafts. This
procedure was designed to determine whether profound viral
infection within the dermis of the allograft would induce re-
jection. Twenty-four days after VV infection, one of the five
mice showed signs of graft rejection, and the graft was com-
pletely rejected 6 days later. The other four mice retained their
grafts with no sign of rejection. MST after initial LCMV in-
fection was .237 days in the total group of 8 infected recipi-
ents versus .251 days in controls (P 5 0.26).
Finally, three of three successful skin allografts on tolerized
recipients that were then infected with LCMV 87 days after
transplantation survived through the end of the experiment
(MST, .221 days relative to infection and .308 days overall).
These experiments collectively indicate that allografts that re-
main stable for ;50 days become remarkably resistant to virus-
induced rejection.
Histology. Histological analysis of control skin grafts that
had survived for 30 days (Fig. 2A) revealed scattered lympho-
cytes in the basal layer of the epidermis and surrounding hair
follicles. Grafts in the process of rejection taken from LCMV-
infected mice 15 days after inoculation (day 16 after transplan-
tation) were characterized by lymphocytic infiltration of the
basal layer of the epidermis and degeneration of the basal
epithelium (Fig. 2B). Apoptotic bodies and a destructive lym-
phocytic infiltrate of the hair follicles were present (Fig. 2B).
The initial phase of rejection was followed by progressive de-
nudation of the graft site. Histologic study of a fully rejected
graft site from an LCMV-infected mouse at day 15 revealed a
subjacent acute and chronic inflammatory reaction (Fig. 2C).
Once an area of necrosis became visible on a graft, it invariably
expanded, and the graft was rejected.
Antigen specificity. To determine whether graft rejection in
response to early LCMV infection (Fig. 1A) was an antigen-
specific phenomenon or simply the consequence of a nonspe-
cific inflammatory response to infection, control isografts were
performed. C57BL/6 mice were treated with a BALB/c DST
and anti-CD154 and then given a C57BL/6 skin isograft in
accordance with the standard protocol. Each of seven recipi-
ents was then infected with LCMV on the day after transplan-
tation. In two independent trials, all seven isografts survived
indefinitely (MST, .259 days) and showed no evidence of
rejection.
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Depletion of CD81 cells delays LCMV-induced rejection of
allografts. CD81 T-cell responses to LCMV in C57BL/6 mice
are known to include H2d alloreactive T cells (19), and in other
systems, CD81 T cells have been found to be important in
mediating graft rejection (20). We therefore tested the hypoth-
esis that CD81 T cells mediated graft rejection in LCMV-
infected mice harboring BALB/c allografts. C57BL/6 mice
were tolerized, transplanted with BALB/c skin allografts, in-
fected with LCMV on the day after transplantation, and then
randomized into three groups of 5 animals each. Group 1
received no further treatment. Group 2 received anti-CD8
MAb on days 0, 1, and 2 after infection. Group 3 received
anti-CD8 MAb on days 8, 9, and 10 after infection. Mice
depleted of CD81 cells immediately after infection (group 2)
became long-term LCMV carriers. The blood concentration of
LCMV was uniformly .105 PFU per ml (range, 1.5 3 105 to
5.3 3 105) 126 days after infection. This finding is consistent
with reports that LCMV persists in the presence of a weak
FIG. 2. LCMV-induced infiltration of leukocytes into the rejecting allograft. C57BL/6 mice were pretreated with a single donor-specific BALB/c spleen cell
transfusion and a brief course of anti-CD154 MAb and then given a BALB/c skin graft as described in Materials and Methods. Mice were either left untreated (A)
or infected with LCMV 1 day after transplantation (B and C). (B) The early phase of graft rejection characterized by mononuclear cell infiltration of the epidermal
basal layer and hair follicles. This is followed by denudation of the graft (C). (Hematoxylin and eosin stain; magnification, 3160).
FIG. 1. Skin allograft survival in uninfected and LCMV-infected mice. C57BL/6 mice were treated with a single donor-specific BALB/c spleen cell transfusion and
a brief course of anti-CD154 MAb and given a BALB/c skin graft as described in Materials and Methods. Transplantation was performed on small groups of animals
over the course of several weeks, as animals became available. A cumulative total of 96 tolerized, transplanted animals was used in this experiment. (A) On the day
after transplantation, a cohort of 20 mice was injected with LCMV; the remaining animals were untreated. Skin allograft survival in this group was statistically
significantly shorter than that in the pool of all other uninfected transplanted mice (P , 0.001). (B) On day 15 after transplantation, 15 recipients from among the
uninfected controls with successful grafts (A) were injected with LCMV. There was no statistically significant difference in overall graft survival between this group and
the pool of all remaining uninfected animals (P 5 0.06). (C) On day 29 after transplantation, seven of the recipients from among the uninfected controls that had not
spontaneously rejected their grafts (B) were selected and injected with LCMV. Graft survival in this group was statistically similar to that observed in the pool of all
remaining uninfected control animals (P 5 0.54). (D) On days 51 to 57 after transplantation, eight recipients from among the uninfected controls that had not
spontaneously rejected their grafts (C) were selected and injected with LCMV. Three of the tolerized recipients infected with LCMV received no other intervention;
one recipient rejected its graft 60 days after LCMV infection. Five of the tolerized recipients infected with LCMV, whose grafts then survived 47 days after infection,
were further challenged with 106 PFU of VV strain WR injected directly into their grafts. One of these animals rejected its graft 30 days later; the remaining grafts
survived through the end of the experiment. Graft survival in the two virus-treated groups was statistically similar to that in the pool of all remaining uninfected controls.
Each panel shows graft survival relative to the day of LCMV injection. Cumulative graft survival was calculated by the method of Kaplan and Meier, which takes into
account the successive removal of mice from the pool of control animals. Vertical bars indicate censored data (i.e., animals with intact grafts at the conclusion of the
study and animals removed at successive intervals for use in the timed infection experiments shown in panels B and C).
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CTL response that would result from treatment with anti-CD8
MAb (18). Mice depleted of CD81 cells on days 8 to 10 (group
3) completely cleared LCMV (,10 PFU/ml of blood), again
consistent with reports that this virus is cleared by CD81 T
cells prior to day 8 after infection (18). In both group 2
(MST 5 39 days) and group 3 (MST 5 32 days), allograft
rejection was significantly delayed compared with group 1 con-
trols that did not receive anti-CD8 MAb (MST 5 21 days; P ,
0.0025) (Fig. 3).
The delay in LCMV-induced allograft rejection in anti-CD8
MAb-treated mice suggests that CD81 T cells participate in
the abrogation of transplantation tolerance in this model sys-
tem. However, the fact that rejection ultimately did occur in
mice depleted of CD81 cells suggests either that the CD8
depletion was incomplete or that an additional rejection mech-
anism, perhaps mediated by CD41 cells, was active. To test the
former possibility, we measured the percentage of CD81 cells
present after graft rejection and observed that depletion was,
in fact, incomplete. After graft rejection, the percentage of
peripheral blood CD81 T cells was found to be 6.1% 6 1.5%
in group 1 (controls, n 5 5), 0.6% 6 0.06% in group 2 (anti-
CD8 treatment on days 0 to 2; n 5 5), and 3.4% 6 0.9% in
group 3 (anti-CD8 treatment on days 8 to 10; n 5 3). The
long-term depletion of CD81 cells appeared to be more com-
plete in group 2 than in group 3, possibly because the number
of CD81 cells was very high on day 8 after infection, when mice
in group 3 were given anti-CD8 MAb. Of interest are the mice
in group 2, whose CD81 T cells were depleted at the time of
infection. They had very low levels of CD81 cells, but none-
theless ultimately rejected their grafts, albeit with delayed ki-
netics. Depletion of CD41 T cells was not studied, as we have
previously shown that anti-CD4 MAb treatment induces allo-
graft rejection in uninfected tolerized mice (5).
Levels of LCMV-induced allospecific CTL activity are de-
pressed in tolerized mice. Because allograft rejection was de-
layed by depletion of CD81 T cells and because LCMV in-
duces anti-H2d-specific CTLs in C57BL/6 mice (19, 22, 28), we
measured splenic anti-H2d-specific CTL activity in trans-
planted, LCMV-infected animals. Groups of thymectomized
and tolerized C57BL/6 recipient mice with intact BALB/c
(H2d) skin allografts were infected with LCMV 1, 15, 50, or 70
days after transplantation. A separate group of thymecto-
mized, LCMV-infected mice that received no graft or other
treatment was used as a positive control. CTL assays were
performed 8 days after infection.
Control levels of CTL activity were high on LCMV-infected
syngeneic targets, very low on uninfected syngeneic targets, and
intermediate on allogeneic uninfected P-815 (H2d) targets
(Fig. 4, filled symbols). Killing of uninfected syngeneic targets
was very low in all experiments (Fig. 4B, E, H, and K). Mice
infected with LCMV 1 day after transplantation evidenced
somewhat reduced but still substantial levels of LCMV-specific
CTL activity on day 8 after infection (Fig. 4A) and cleared the
virus. This finding is noteworthy because it documents that,
although reduced, a protective LCMV-specific CTL response
was not prevented by the anti-CD154 MAb and the trauma of
surgery. There was no response to uninfected syngeneic cells
(Fig. 4B), and the allografted, infected mice displayed only low
levels of cytotoxicity against P-815 targets (Fig. 4C). LCMV-
infected mice given allogeneic BALB/c splenocytes, anti-
CD154 MAb, and skin isografts also displayed very low levels
of allospecific CTL activity (data not shown). This demon-
strates that the continued presence of an allogeneic skin graft
was not required to maintain relatively depressed levels of
virus-induced allospecific CTL activity in mice previously toler-
ized with BALB/c splenocytes.
Allografted mice infected with LCMV 15 days after trans-
plantation generated virus-specific CTL responses nearly as
high as those generated by the thymectomized nontolerized
control mice (Fig. 4D). In contrast, although some killing of
allogeneic P-815 targets was detectable, the tolerized mice
exhibited substantially lower allospecific CTL activity than did
the control thymectomized mice (Fig. 4F). Similar results were
obtained from mice infected with LCMV 50 (Fig. 4G, H, and
I) or 70 (Fig. 4J, K, and L) days after transplantation. With the
sole exception of one transplanted, infected mouse with high
allospecific CTL activity (Fig. 4F, open diamond), generally
low but still detectable levels of allospecific CTL activity were
observed. In comparison with the thymectomized, nontolerized
controls, the LCMV-induced allospecific CTL activity in all
groups of tolerized, grafted, virus-infected mice was signifi-
cantly, but not completely, eliminated. This finding was also
true for mice that were infected on the day after transplanta-
tion and were destined to reject their allografts.
In contrast to the high levels of virus-specific and allospecific
cytotoxicity observed on day 8 postinfection in thymectomized
control mice (Fig. 4C), CTL activity was undetectable on day
15 postinfection (data not shown). This was true both in con-
trol, nontransplanted, thymectomized mice and in tolerized
mice given LCMV on the day after transplantation (data not
shown). The results confirm the transient nature of the LCMV-
induced CTL response in the spleen. They also show that no
delayed allospecific CTL response was generated in the
spleens of mice harboring allografts. The data do not, however,
exclude the possibility that allospecific CTL may have infil-
trated the allografts.
poly I:C does not abrogate graft survival in mice treated
with DST and anti-CD154 MAb. poly I:C is a synthetic double-
stranded polyribonucleotide. Presumably due to structural re-
semblance to double-stranded viral RNA, poly I:C elicits cy-
tokine responses that mimic the early stages of viral infection.
These responses include the stimulation of type I interferon
interleukin-1, tumor necrosis factor alpha, and the activation
of NK cells, macrophages, and endothelial cells (8). To deter-
FIG. 3. Skin allograft survival in LCMV-infected mice treated with anti-CD8
MAb. C57BL/6 mice were pretreated with a single donor-specific BALB/c spleen
cell transfusion and a brief course of anti-CD154 MAb and then given a BALB/c
skin graft as described in Materials and Methods. All mice were infected with
LCMV 1 day after transplantation (arrow) and randomized into three groups.
Group 1 received no further treatment. Group 2 was treated with anti-CD8 MAb
on days 0, 1, and 2 relative to infection (days 1 to 3 relative to transplantation).
Group 3 was treated with anti-CD8 MAb on days 8, 9, and 10 relative to infection
(days 9, 10, and 11 relative to transplantation), by which time the induced T-cell
response has usually cleared LCMV infection. Graft survival in groups 2 and 3
differs from that in group 1, where P values are #0.025.
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FIG. 4. Effect of DST and anti-CD154 MAb on LCMV-induced CTL activity. C57BL/6 mice were pretreated with a single donor-specific BALB/c spleen cell
transfusion and a brief course of anti-CD154 MAb and then given a BALB/c skin graft as described in Materials and Methods. Groups of mice bearing intact grafts
were infected with LCMV on day 1, 15, 50, or 70 after skin transplantation. T cells from these mice were tested in 7- to 8-h chromium-51-release assays for cytotoxicity
against LCMV-infected syngeneic MC57G cells (A, D, G, and J), uninfected MC57G cells (B, E, H, and K), or allogeneic P-815 cells (C, F, I, and L). Open symbols
represent the percent lysis mediated by splenocytes from mice treated with DST and anti-CD154 MAb and skin grafted. Solid symbols represent cytotoxicity mediated
by control thymectomized mice infected with LCMV. In the day 70 experiment, the 3-3 symbols refer to lysis by cells from LCMV-infected normal nonthymectomized
mice that were used as the controls.
VOL. 74, 2000 VIRAL INFECTION AND TRANSPLANTATION TOLERANCE 2215
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
mine if the deleterious effect of peritransplant LCMV infection
on graft survival was in part due to nonspecific inflammation,
thymectomized C57BL/6 recipients were treated with DST and
anti-CD154 MAb and given BALB/c skin allografts. These
mice were then given either no further treatment (n 5 5) or
poly I:C (n 5 5) 1 day after transplantation. MST was .113
days in both controls and in poly I:C-treated recipients.
Infection with other viruses at the time of tolerance induc-
tion. These data document that tolerized mice inoculated with
LCMV 1 day after transplantation control the infection but
rapidly reject their grafts. We next examined the response of
tolerized, thymectomized C57BL/6 mice to various other vi-
ruses that were inoculated 1 day after transplantation of
BALB/c skin grafts. The results are summarized in Table 1.
Only 3 of 19 tolerized, thymectomized, but uninfected con-
trol mice rejected their grafts by day 75 after transplantation.
This rate of skin allograft survival is consistent with previous
reports (15).
Seven of eight tolerized, transplanted mice infected i.p. with
106 PFU of VV in two experiments died within 1 week of
infection. In contrast, none of six mice treated with DST and
anti-CD154 MAb but no skin graft died when given 106 PFU of
VV, suggesting that the surgical trauma of transplantation may
have enhanced the susceptibility of these mice to infection.
Tolerized, grafted mice given either 105 PFU (n 5 6) or 104
PFU (n 5 6) of VV uniformly survived the infection (Table 1).
The effect of VV infection on graft survival in mice that cleared
the infection was relatively minimal. By day 75 after infection,
only 1 of 13 surviving VV-infected mice rejected its graft.
Tolerized, grafted mice given either 104 (n 5 11), 3 3 104
(n 5 5), or 105 (n 5 5) PFU of MCMV i.p. uniformly survived;
normal mice given 106 PFU of the same stock died. This result
demonstrates that the tolerized mice were able to control the
potentially lethal virus. By day 75 after transplantation, 4 of 21
tolerized recipients rejected their grafts after MCMV infec-
tion, but this allograft survival distribution was not statistically
different from that observed in tolerized, uninfected mice (Ta-
ble 1).
Tolerized mice survived infection with PV at a dose of 5 3
106 PFU. PV, like LCMV, was a potent inducer of graft rejec-
tion; three of five grafts on PV-infected mice were rejected by
day 22, and a fourth by day 61. PV and LCMV are both
arenaviruses.
These results suggest that tolerization and transplantation
procedures may make a host more susceptible to some but not
all viral infections. In general, however, tolerized mice con-
trolled virus infections. The data demonstrate that viruses dif-
fer greatly in their ability to induce acute graft rejection in
recently tolerized recipients. Because LCMV very rapidly in-
duced the rejection of BALB/c allografts whereas VV did not,
we hypothesized that an LCMV gene product expressed in a
VV recombinant might induce rejection by eliciting T cells
cross-reactive with the allograft. To test this hypothesis, toler-
ized, skin-grafted mice were inoculated i.p. with 8 3 106 PFU
of either VV-NP or VV-GP. These high doses were used
because VV recombinants grow more poorly in vivo than does
wild-type VV. Grafts on four of five of the VV-NP-infected
mice showed signs of rejection during the first 10 days after
infection. The grafts shrank to 20 to 60% of the normal size but
then stabilized. Only one graft was eventually rejected on day
59. Grafts on five VV-GP-infected mice showed no signs of
rejection at any time and survived throughout the duration of
this experiment. Studies into the nature of this response are
continuing.
DISCUSSION
These results demonstrate that acute viral infection can in-
terfere with tolerance induction and reduce skin allograft sur-
vival in mice tolerized with DST and anti-CD154 MAb. In the
majority of cases, however, the tolerized, transplanted recipi-
ents cleared the infection and survived. Infection at later time
points after tolerization had progressively less effect on graft
survival and no deleterious effect on recipient survival.
Statistically significant effects of viral infection on graft sur-
vival were observed only when infection occurred soon after
transplantation. This observation suggests that cells responsi-
ble for rejection may initially be only partially suppressed or
tolerized and that this early tolerant state may be overcome by
factors induced during the viral infection. After grafts had
survived for several weeks, however, LCMV infection no
longer interfered with the allotolerant state.
Our data suggest that the mechanism by which infection in
the peritransplant period interferes with tolerization and graft
survival involves CD81 T cells. LCMV-induced CD81 T-cell-
mediated allograft rejection could be the consequence of T-cell
cross-reactivity between self-presented LCMV peptides and
alloantigens. Alternatively, rejection could be the consequence
of bystander stimulation of non-cross-reactive but anergized or
“ignorant” allospecific T cells whose TcR can be stimulated by
the allograft (10). However, if acute graft rejection were a
consequence of bystander stimulation, it is surprising that poly
I:C, VV, and MCMV were so inefficient in this process. These
results, coupled with the results obtained with anti-CD8 MAb,
suggest that the abrogation of graft survival by LCMV infec-
TABLE 1. Survival of skin allografts on tolerized mice infected with various virusesa
Virus Dose (PFU) n Graft survival (days) MST
VV Wt 106 8b .75b
VV Wt 105 6 10, .75, .75, .75, .75, .75 .75
VV Wt 104 6 .75, .75, .75, .75, .75, .75 .75
MCMV 105 5 10, .75, .75, .75, .75 .75
MCMV 3 3 104 5 36, 41, .75, .75, .75 .75
MCMV 104 11 One graft, 10; ten grafts, .75 each .75
PV 5 3 106 5 21, 21, 22, 61, .64 22c
VV-NP 8 3 106 5 59, .64, .64, .64, .64 .64
VV-GP 8 3 106 5 .64, .64, .64, .64, .64 .64
Uninfected NA 19 7, 8, 20, .64, .64, .64, .64, and 12 grafts, .75 each .75
a C57BL/6 mice were treated with DST and anti-CD154 MAb and grafted with BALB/c skin as described in Materials and Methods. One day after skin grafting, mice
were injected i.p. with virus as indicated. The day of graft rejection is indicated. Wt, wild type.
b A total of 7 of the 8 mice were found dead before day 14, but had intact grafts to that point.
c Significantly different from values obtained with uninfected controls (P 5 0.013).
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tion immediately after transplantation is more likely to be the
result of allospecific CTL generation than the result of non-
specific inflammation. Surprisingly, however, only very low lev-
els of LCMV-induced allospecific CTL could be detected in
the spleen during LCMV-induced graft rejection. It is possible
that some of the CTLs migrated into the graft and were there-
fore underrepresented in the spleen. Consistent with this con-
cept, rejecting grafts had significant lymphocyte infiltrates, and
rejection was impaired by the depletion of CD81 T cells.
The resistance of grafts to LCMV-induced allospecific CTLs
at later time points could involve several factors. We have
shown in both the present study and previous reports (15) that
after 7 weeks of graft survival, a more stable form of tolerance
or suppression is present. This appears not to be due to com-
plete absence of graft-rejecting T cells because alloreactive
cells can be detected in uninfected animals bearing grafts for
.100 days (15). Although the present data show that a long-
term tolerant state cannot be overcome by infection, it is
known that it can be broken by depletion of CD41 cells (15).
It is plausible to suggest that the difference in the ability of low
levels of alloreactive CD81 CTLs to abrogate allograft toler-
ance over time is due to the development of a population of
CD41 suppressor T cells.
LCMV, VV, PV, and MCMV all induce anti-H2d allospe-
cific CTL in C57BL/6 mice, but LCMV is a more potent stim-
ulator of CTL than are the other viruses (19, 22, 28). LCMV
appears to be more efficient than VV or MCMV in inducing
graft rejection, but to date only LCMV has been investigated in
detail. It is noteworthy that in one experiment, PV, which is
distantly related to LCMV by virtue of being an arenavirus,
induced graft rejection with a time course similar to that of
LCMV.
Clonal exhaustion of high-affinity LCMV-specific CTLs oc-
curs under conditions of high antigen load and persistent in-
fection (18). Treatment with anti-CD8 MAb led to LCMV
persistence but still allowed for graft rejection. These findings
indicate that high-affinity LCMV-specific CD81 CTLs are not
required for rejection, but evidence has suggested that some
LCMV-induced allospecific CTLs have higher affinity to allo-
geneic targets than to LCMV-infected syngeneic targets with
which they cross-react (19).
It is noteworthy that, unlike LCMV and PV, VV had no
detectable effect on graft survival. In an attempt to determine
the mechanism underlying this difference, we investigated the
ability of immunogenic LCMV-encoded proteins in VV vec-
tors to enhance the ability of VV to stimulate graft rejections.
Our initial investigation has shown that a VV-NP recombinant
substantially reduced graft size after transplantation but did
not ultimately lead to complete graft rejection. Additional
analysis of VV recombinants is in progress.
For the most part, tolerized and transplanted animals sur-
vived infection, and as shown with LCMV, mounted a steril-
izing CTL response. Only high-dose VV infection was associ-
ated with recipient mortality. It should be noted that the fatal
outcome required both the tolerization procedure and surgical
trauma; tolerized mice that had not been operated on survived
the infection.
In conclusion, we demonstrate that DST and anti-CD154
MAb induce a state of allotolerance that can be broken shortly
after transplantation by certain viral infections. In addition,
infection with at least one virus during treatment may endan-
ger host survival. We recognize that data from this limited
survey of infection in murine graft recipients cannot be extrap-
olated with any assurance to other species. However, clinical
trials of tolerance-based transplantation are being planned,
and the data do suggest that it may be prudent to initially
isolate patients during tolerance induction in order to facilitate
the procedure and to reduce the risk of infection.
ACKNOWLEDGMENTS
We thank Linda Paquin, Linda Leehy, and Carey L. O’Donnell for
technical assistance.
This work was supported in part by grants AR35506 and 3PO3-
DK32520 and by program projects 1PO1-DK53006 and 1PO1-AI42669
from the National Institutes of Health.
REFERENCES
1. Alexander-Miller, M. A., K. Burke, U. H. Koszinowski, T. H. Hansen, and
J. M. Connolly. 1993. Alloreactive cytotoxic T lymphocytes generated in the
presence of viral-derived peptides show exquisite peptide and MHC speci-
ficity. J. Immunol. 151:1–10.
2. Braciale, T. J., M. E. Andrew, and V. L. Braciale. 1981. Simultaneous ex-
pression of H-2-restricted and alloreactive recognition by a cloned line of
influenza virus-specific cytotoxic T lymphocytes. J. Exp. Med. 153:1371–1376.
3. Briggs, J. D., M. C. Timbury, A. M. Paton, and P. R. Bell. 1972. Viral
infection and renal transplant rejection. Br. Med. J. 4:520–522.
4. Burrows, S. R., R. Khanna, J. M. Burrows, and D. J. Moss. 1994. An
alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL)
cross-reactive with a single Epstein-Barr virus CTL epitope: implications for
graft-versus-host disease. J. Exp. Med. 179:1155–1161.
5. Caldas, C., and R. Ambinder. 1995. Epstein-Barr virus and bone marrow
transplantation. Curr. Opin. Oncol. 7:102–106.
6. Clark, L. B., T. M. Foy, and R. J. Noelle. 1996. CD40 and its ligand. Adv.
Immunol. 63:43–78.
7. Daniel, C., S. Horvath, and P. M. Allen. 1998. A basis for alloreactivity:
MHC helical residues broaden peptide recognition by the TCR. Immunity
8:543–552.
8. Doukas, J., A. H. Cutler, and J. P. Mordes. 1994. Polyinosinic:polycytidylic
acid is a potent activator of endothelial cells. Am. J. Pathol. 145:137–147.
9. Ehl, S., J. Hombach, P. Aichele, H. Hengartner, and R. M. Zinkernagel.
1997. Bystander activation of cytotoxic T cells: studies on the mechanism and
evaluation of in vivo significance in a transgenic mouse model. J. Exp. Med.
185:1241–1251.
10. Ehl, S., J. Hombach, P. Aichele, T. Rulicke, B. Odermatt, H. Hengartner, R.
Zinkernagel, and H. Pircher. 1998. Viral and bacterial infections interfere
with peripheral tolerance induction and activate CD81 T cells to cause
immunopathology. J. Exp. Med. 187:763–774.
11. Foy, T. M., A. Aruffo, J. Bajorath, J. E. Buhlmann, and R. J. Noelle. 1996.
Immune regulation by CD40 and its ligand gp39. Annu. Rev. Immunol.
14:591–617.
11a.Institute of Laboratory Animal Resources. 1996. Guide for the care and use
of laboratory animals. National Research Council, National Academy of
Sciences, Washington, D.C.
12. Kadakia, M. P., W. B. Rybka, J. A. Stewart, J. L. Patton, F. R. Stamey, M.
Elsawy, P. E. Pellett, and J. A. Armstrong. 1996. Human herpesvirus 6:
infection and disease following autologous and allogeneic bone marrow
transplantation. Blood 87:5341–5354.
13. Kaplan, E. L., and P. Meier. 1958. Nonparametric estimation from incom-
plete observations. J. Am. Stat. Assoc. 53:457–481.
14. Larsen, C. P., and T. C. Pearson. 1997. The CD40 pathway in allograft
rejection, acceptance, and tolerance. Curr. Opin. Immunol. 9:641–647.
15. Markees, T. G., N. E. Phillips, E. J. Gordon, R. J. Noelle, L. D. Shultz, J. P.
Mordes, D. L. Greiner, and A. A. Rossini. 1998. Long-term survival of skin
allografts induced by donor splenocytes and anti-CD154 antibody in thymec-
tomized mice requires CD41 T cells, interferon-gamma, and CTLA4. J. Clin.
Investig. 101:2446–2455.
16. Markees, T. G., N. E. Phillips, R. J. Noelle, L. D. Shultz, J. P. Mordes, D. L.
Greiner, and A. A. Rossini. 1997. Prolonged survival of mouse skin allografts
in recipients treated with donor splenocytes and antibody to CD40 ligand.
Transplantation 64:329–335.
17. May, A. G., R. F. Betts, R. B. Freeman, and C. H. Andrus. 1978. An analysis
of cytomegalovirus infection and HLA antigen matching on the outcome of
renal transplantation. Ann. Surg. 187:110–117.
18. Moskophidis, D., F. Lechner, H. Pircher, and R. M. Zinkernagel. 1993. Virus
persistence in acutely infected immunocompetent mice by exhaustion of
antiviral cytotoxic effector T cells. Nature 362:758–761.
19. Nahill, S. R., and R. M. Welsh. 1993. High frequency of cross-reactive
cytotoxic T lymphocytes elicited during the virus-induced polyclonal cyto-
toxic T lymphocyte response. J. Exp. Med. 177:317–327.
20. Rossini, A. A., D. L. Greiner, and J. P. Mordes. 1999. Induction of immu-
nological tolerance for transplantation. Physiol. Rev. 79:99–141.
21. Schwartz, R. H. 1990. A cell culture model for T lymphocyte clonal anergy.
Science 248:1349–1356.
22. Sheil, J. M., M. J. Bevan, and L. Lefrancois. 1987. Characterization of
dual-reactive H-2Kb-restricted anti-vesicular stomatitus virus and alloreac-
VOL. 74, 2000 VIRAL INFECTION AND TRANSPLANTATION TOLERANCE 2217
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
tive cytotoxic T cells. J. Immunol. 138:3654–3660.
23. Simmons, R. L., C. Lopez, H. J. Balfour, J. Kalis, L. C. Rattazzi, and J. S.
Najarian. 1974. Cytomegalovirus: clinical virological correlations in renal
transplant recipients. Ann. Surg. 180:623–634.
24. Speir, J. A., K. C. Garcia, A. Brunmark, M. Degano, P. A. Peterson, L.
Teyton, and I. A. Wilson. 1998. Structural basis of 2C TCR allorecognition of
H-2Ld peptide complexes. Immunity 8:553–562.
25. Strang, G., and A. B. Rickinson. 1987. Multiple HLA class I-dependent
cytotoxicities constitute the “non-HLA-restricted” response in infectious
mononucleosis. Eur. J. Immunol. 17:1007–1013.
26. Tomkinson, B. E., R. Maziarz, and J. L. Sullivan. 1989. Characterization of
the T cell-mediated cellular cytotoxicity during acute infectious mononucle-
osis. J. Immunol. 143:660–670.
27. Whitton, J. L., P. A. Southorn, and M. B. Oldstone. 1999. Analyses of the
cytotoxic T lymphocyte responses to glycoprotein and nucleoprotein com-
ponents of lymphocytic choriomeningitis virus. Virology 162:321–327.
28. Yang, H. Y., P. L. Dundon, S. R. Nahill, and R. M. Welsh. 1989. Virus-
induced polyclonal cytotoxic T lymphocyte stimulation. J. Immunol. 142:
1710–1718.
2218 WELSH ET AL. J. VIROL.
 at UNIV O
F M
ASS M
ED SCH on August 4, 2008 
jvi.asm.org
D
ow
nloaded from
 
